John P. Gabrielson, Ph.D.

Dr. John Gabrielson has over 20 years of experience developing biologics.  Prior to joining Pharmefex, John was Senior Vice President of Pharmaceutical Development at Sidewinder Therapeutics, executing the company's CMC strategy.  Prior to Sidewinder, he launched Similis Bio as SVP of Biosimilars at JSR Life Sciences. At KBI Biopharma, he served as SVP of Analytical and Formulation Sciences, leading a team of 400 scientists and overseeing analytical support for over 100 client programs. In 2015, John co-founded Elion Labs, where as President and CEO, he shaped the company's strategy and executed its business plan. John’s extensive experience also includes leadership roles at Amgen, where he directed an analytical organization focused on developing and validating analytical methods for biologics, from late-stage clinical trials through post-market approval. Throughout his career, John has been at the forefront of advancing analytical methods in biopharmaceuticals, evidenced by his numerous publications, invited presentations, and patent. He brings a deep understanding of the complexities of biologics development across many modalities, including development of enzymes, therapeutic antibodies, multi-specific proteins, biosimilars and antibody drug conjugates. A seasoned leader, John has a proven track record of building and scaling successful organizations and a passion for driving innovation.  He holds a Ph.D. in Chemical Engineering from the University of Colorado, Boulder.